

Lacy MQ, McCurdy AR. Pomalidomide. *Blood*. 2013;122(14):2305-2309.

On page 2307 in the 3 October 2013 issue, there is an error in the text. The number of months of median progression-free survival, “82,” should have read “8.2.” Also, the corresponding reference citation, 32, was missing. The fourth sentence of the first paragraph reads, “Median progression-free survival was 82 months.” The sentence should have read, “Median progression-free survival was 8.2 months.”³²

32. Mark TM, Boyer A, Rossi AC, et al. ClAPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. *ASH Annual Meeting Abstracts*. 2012;120(21):77.

© 2014 by The American Society of Hematology

Oft M. No immunosurveillance in human IL-10R deficiency. *Blood*. 2013;122(23):3702-3703.

On pages 3702 and 3703 in the 28 November 2013 issue, there are errors in the text. In the third sentence of first paragraph on page 3702, there is a missing comma. The text reads, “To complicate the picture, IL-10 enhances the proliferation and survival of the differentiation, the expression of major histocompatibility complex class II (MHC II) molecules, immunoglobulins, and isotype switching in B cells.” It should have read, “To complicate the picture, IL-10 enhances the proliferation and survival of, the differentiation, the expression of major histocompatibility complex class II (MHC II) molecules, immunoglobulins, and isotype switching in B cells.”

On page 3703, after the first full sentence, there is a missing sentence, which should have read, “Treatment of tumor-bearing mice with a PEGylated form of IL-10 increased the tumor-infiltrating CD8 T cells, their activation, and tumor rejection.”

Also on page 3703, in the second sentence of the second paragraph, there is a missing number regarding the number of patients for which genetic mutations in IL-10R were recently found. The correct number of patients is “in 4 of 9 patients.” The text reads, “Closing the species gap between mice and humans, genetic mutations in IL-10R were recently found in 4 of patients with very-early-onset IBD, a severe genetic form of colitis that develops within the first years of life.¹⁰” The text should read, “Closing the species gap between mice and humans, genetic mutations in IL-10R were recently found in 4 of 9 patients with very-early-onset IBD, a severe genetic form of colitis that develops within the first years of life.¹⁰”

10. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med*. 2009;361(21):2033-2045.

© 2014 by The American Society of Hematology

Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. *Blood*. 2013;122(23):3723-3734.

On page 3725 in the 28 November 2013 issue, there is a typographical error. The first line (the sentence begins on page 3724) reads, “Similar results were obtained in a trial comparing FCR without FC in relapsed CLL without demonstrating a benefit for OS.⁴⁰” The sentence should have read, “Similar results were obtained in a trial comparing FCR with FC in relapsed CLL without demonstrating a benefit for OS.⁴⁰”

⁴⁰Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. *J Clin Oncol*. 2010;28(10):1756-1765.

© 2014 by The American Society of Hematology